Ushbu ishga iqtibos qilgan ishlar

2 ta ish

Ish: PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

1. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   MaqolaCAR-T cell therapy researchJournal of Hematology & Oncology20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.000083

2. Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy

   Mutaz Jamal Al-khreisat, Waleed K. Abdulsahib, Ihsan Khudhair Jasim +6

   MaqolaCancer Immunotherapy and BiomarkersAnnals of Hematology20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.009488